BDBM622524 US20230312583, Compound VI-1
SMILES COc1cc(Nc2ncc3ccc4nc(C)n(C(C)C)c4c3n2)ncc1N1CCOCC1
InChI Key InChIKey=UYDMDSBIXKYMQD-UHFFFAOYSA-N
Data 7 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 7 hits for monomerid = 622524
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 1.55nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 1.5nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetMast/stem cell growth factor receptor Kit(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 46nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 388nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 89.1nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 245nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 397nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair